Advertisement
ATHE vs EYPT
Which Stock Would AI Choose? Alterity Therapeutics (ATHE) vs. EyePoint Pharmaceuticals (EYPT) Stock Comparison
Key Takeaways
- ATHE (Alterity Therapeutics) has gained positive momentum on FDA (U.S. Food and Drug Administration) alignment for its ATH434 Phase 3 program in Multiple System Atrophy, while EYPT (EyePoint Pharmaceuticals) has faced heavy selling after its DURAVYU LUGANO Phase 3 trial missed its primary endpoint.
- Relative performance diverges sharply: ATHE has been supported by regulatory milestones, while EYPT has declined sharply in recent months on binary clinical risk.
- ATHE carries a consensus "Strong Buy" analyst rating, whereas EYPT has seen recent downgrades to "Hold" following the Phase 3 miss.
- Both companies are pre-revenue, loss-making clinical-stage biotechs, making them higher-risk, catalyst-driven equities.
- Tickeron AI Verdict: Based on trend consistency, regulatory progress, and relative positioning, Tickeron's AI currently favors ATHE over EYPT.
- For deeper coverage, explore ATHE Major News and ATHE Today's Price Move, as well as EYPT Major News and EYPT Today's Price Move.
- To see how AI-powered strategies are navigating this market, explore Trending AI Robots.
Introduction
This stock comparison examines two clinical-stage biotechnology companies with very different recent trajectories. ATHE (Alterity Therapeutics) is an Australian-headquartered developer of treatments for neurodegenerative disorders, while EYPT (EyePoint Pharmaceuticals) is a U.S.-based developer of sustained-release therapies for serious retinal diseases. Both are speculative, pre-profit equities whose market positioning hinges on upcoming clinical and regulatory catalysts. Traders and investors who follow catalyst-driven biotech names, or who seek to compare relative performance and risk across the sector, may find this analysis useful for understanding how the two companies stack up in the current market environment.
ATHE Overview and Recent Performance
Alterity Therapeutics is focused on developing disease-modifying therapies for Parkinsonian and other neurodegenerative conditions, most notably Multiple System Atrophy (MSA), a rare and progressive disorder with no approved treatment. Its lead candidate, ATH434, is an orally administered small molecule designed to inhibit the aggregation of pathological proteins linked to neurodegeneration.
Recent market activity has been shaped by meaningful regulatory progress. In recent weeks, Alterity announced it had reached alignment with the FDA on the pivotal Phase 3 program for ATH434 in MSA following an End-of-Phase 2 meeting, covering study design, dosing, and duration. The company also reported that a U.S. composition-of-matter patent was granted for ATH434, extending protection to 2045, and that the candidate carries Fast Track and Orphan Drug designations from the FDA. These developments have supported sentiment, contributing to a firmer relative performance despite the company's continued operating losses and modest cash position.
EYPT Overview and Recent Performance
EyePoint Pharmaceuticals develops sustained-release drug delivery treatments for serious eye diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead program, DURAVYU (vorolanib), is an investigational sustained-delivery therapy designed to reduce injection burden for patients receiving anti-VEGF treatments.
Recent market activity has been dominated by disappointing clinical news. The company's LUGANO Phase 3 trial of DURAVYU in wet AMD did not meet its primary endpoint in the full patient population, triggering a sharp, high-volume sell-off. Although an ad hoc analysis and secondary endpoints showed reductions in treatment burden, the headline miss weighed heavily on shares and prompted analyst downgrades. Management has pointed to the second pivotal trial, LUCIA, with data expected in the fourth quarter of 2026, as the next major catalyst. Against this backdrop, EYPT's stock has declined substantially in recent months, reflecting elevated binary risk.
Trending AI Robots
Tickeron's Trending AI Robots page is a curated showcase of the platform's best-performing automated trading strategies. Tickeron maintains hundreds of AI trading bots that collectively monitor and trade thousands of different tickers, each built with its own trading style, strategy, timeframe, performance record, and set of target securities. Because not every bot suits every market regime, only the strategies considered most suitable for current conditions earn a place in the Trending AI Robots section, where users can review their statistics and historical results. For investors and traders evaluating names like ATHE and EYPT, this is a practical way to observe how systematic, rules-based approaches are navigating today's markets. Explore Trending AI Robots to review the current lineup.
Head-to-Head Comparison
The two companies differ fundamentally in therapeutic focus, recent momentum, and risk profile. ATHE operates in the rare-disease neurology space, targeting an underserved indication in MSA, which offers potential regulatory advantages such as Orphan Drug designation. EYPT operates in the large but highly competitive retinal market, where established anti-VEGF therapies from major pharmaceutical companies create a tougher commercial landscape.
On momentum, the contrast is stark. ATHE's recent performance has been supported by a string of favorable regulatory and clinical updates, lending a more consistent upward bias to sentiment. EYPT, by contrast, has been pressured by a pivotal trial miss and subsequent rating downgrades, leaving its near-term outlook tied to a single upcoming readout. In terms of risk, both carry substantial execution and financing risk, but EYPT's recent data setback introduces a more pronounced binary element to its story. From a market positioning standpoint, ATHE currently presents a steadier trend with clearer near-term catalysts, while EYPT offers potentially larger optionality but with considerably greater uncertainty.
Tickeron AI Verdict
Based on observable factors such as trend consistency, regulatory alignment, and the relative quality of recent catalysts, Tickeron's AI would currently favor ATHE over EYPT. ATHE's confirmed Phase 3 pathway, granted patent protection, and positive Phase 2 efficacy signals provide a more stable foundation for continued relative strength. EYPT, while retaining substantial longer-term potential if the LUCIA trial succeeds, currently reflects a less favorable risk-reward profile following its primary-endpoint miss. This assessment is probabilistic rather than definitive, reflecting the inherent volatility of clinical-stage biotech equities and the potential for outcomes to shift with new data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHE is a Hold and EYPT is a Hold.
ATHE's RSI Indicator recovers from oversold territory
The RSI Oscillator for ATHE moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 26 of the 32 cases the stock moved higher. This puts the odds of a move higher at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on ATHE as a result. In 75 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for ATHE just turned positive on October 30, 2026. Looking at past instances where ATHE's MACD turned positive, the stock continued to rise in 39 of 52 cases over the following month. The odds of a continued upward trend are 75%.
Following a +8.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATHE advanced for three days, in 147 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ATHE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for ATHE moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATHE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ATHE entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.036) is normal, around the industry mean (3.498). P/E Ratio (-1.821) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. ATHE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATHE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EYPT in +12.25% Uptrend, rising for three consecutive days on November 10, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EYPT advanced for three days, in 238 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 63 cases where EYPT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on EYPT as a result. In 58 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for EYPT just turned positive on November 02, 2026. Looking at past instances where EYPT's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
EYPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EYPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for EYPT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.187) is normal, around the industry mean (3.498). P/E Ratio (-0.096) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.380) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (101.010) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. EYPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EYPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ATHE | EYPT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 47 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 62 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 99 | |
PRICE GROWTH RATING 1..100 | 85 | 99 | |
P/E GROWTH RATING 1..100 | 10 | 5 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EYPT's Valuation (62) in the Pharmaceuticals Major industry is in the same range as ATHE (85) in the Biotechnology industry. This means that EYPT’s stock grew similarly to ATHE’s over the last 12 months.
EYPT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ATHE (100) in the Biotechnology industry. This means that EYPT’s stock grew similarly to ATHE’s over the last 12 months.
ATHE's SMR Rating (98) in the Biotechnology industry is in the same range as EYPT (99) in the Pharmaceuticals Major industry. This means that ATHE’s stock grew similarly to EYPT’s over the last 12 months.
ATHE's Price Growth Rating (85) in the Biotechnology industry is in the same range as EYPT (99) in the Pharmaceuticals Major industry. This means that ATHE’s stock grew similarly to EYPT’s over the last 12 months.
EYPT's P/E Growth Rating (5) in the Pharmaceuticals Major industry is in the same range as ATHE (10) in the Biotechnology industry. This means that EYPT’s stock grew similarly to ATHE’s over the last 12 months.
| ATHE | EYPT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 78% |
| Stochastic ODDS (%) | N/A | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 75% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Advances ODDS (%) | 16 days ago 73% | 2 days ago 83% |
| Declines ODDS (%) | 7 days ago 89% | 7 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 80% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATHE’s FA Score shows that 1 FA rating(s) are green while EYPT’s FA Score has 1 green FA rating(s).
- ATHE’s FA Score: 1 green, 4 red.
- EYPT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ATHE’s TA Score shows that 5 TA indicator(s) are bullish while EYPT’s TA Score has 6 bullish TA indicator(s).
- ATHE’s TA Score: 5 bullish, 3 bearish.
- EYPT’s TA Score: 6 bullish, 2 bearish.
Price Growth
ATHE (@Biotechnology) experienced а -6.07% price change this week, while EYPT (@Biotechnology) price change was +1.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
EYPT is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EYPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with ATHE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then ATHE could also see price increases.
| Ticker / NAME | Correlation To EYPT | 1D Price Change % | ||
|---|---|---|---|---|
| EYPT | 100% | +11.66% | ||
| ATHE - EYPT | 54% Loosely correlated | -4.53% | ||
| KROS - EYPT | 40% Loosely correlated | +1.74% | ||
| AMLX - EYPT | 38% Loosely correlated | +2.32% | ||
| KYTX - EYPT | 37% Loosely correlated | -1.74% | ||
| VTGN - EYPT | 37% Loosely correlated | -0.70% | ||
More | ||||